Generic Name: buprenorphine
Brand Name: Sublocade
Manufacturer: Indivior Canada Ltd.
Indications: Opioid use disorder, treatment
Manufacturer Requested Reimbursement Criteria1: For the treatment of moderate-to-severe opioid use disorder in adults. Sublocade should be used as part of a complete treatment plan that includes counseling and psychosocial support.
Submission Type: New
Project Status: Active
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||July 25, 2018|
|Patient group input closed||September 14, 2018|
- No patient input submission received
|Submission received||December 20, 2018|
|Submission accepted for review||January 11, 2019|
|Review initiated||January 14, 2019|
|Draft CADTH review report(s) sent to applicant||March 28, 2019|
|Comments from applicant on draft CADTH review report(s) received||April 08, 2019|
|Redaction requests from applicant on draft CADTH review report(s) received||April 15, 2019|
|CADTH review team's comments on draft CADTH review report(s) sent to applicant||May 03, 2019|
|Canadian Drug Expert Committee (CDEC) meeting||May 15, 2019|
|CDEC recommendation & redacted CADTH review report(s) sent to applicant and drug plans||May 28, 2019
May 30, 2019